Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

The CCOI Myopia Workshop in Paris on September 8, 2025, will bring together global experts to address the rising epidemic of myopia. (Image credit: AdobeStock/racesy) As myopia rates continue to climb globally—emerging as a major concern not only in Asia…

In advance of the upcoming CCOI Myopia Workshop, scheduled for September 8 in Paris, France, Michael X. Repka, MD, MBA—program co-chair of the event and current president of the American Academy of Ophthalmology—spoke about the challenges and opportunities facing the…

Demonstration of the identifeye HEALTH device in use. Photo owned by identifeye HEALTH and used with permission identifeye HEALTH has launched its retinal screening platform and is now delivering results to patients through clinics and community programs. The platform is…

In this inaugural episode of iOpeners, host Nicole Bajic, MD, a comprehensive ophthalmologist at the Cole Eye Institute in Cleveland, Ohio, speaks with Bill Trattler, MD, a refractive, corneal, and cataract eye surgeon at the Center For Excellence In Eye…

This conversation features Daniella Ferrara, Chief Medical Officer for TopCon Healthcare, discussing the transformative potential of artificial intelligence in retinal imaging and ophthalmology. Ferrara, an ophthalmologist and retina specialist with 25 years of experience in retinal imaging innovation. The discussion…

(Image credit: ©Hand Robot/AdobeStock) Kriya Therapeutics reported in an SEC filing it has raised $313.3 million in a recent funding round.1 The filing does not detail fund specificity or funding sources but rather only states two investors participated in the…
2-day ‘Eye-Conic’ conference kicks off in Chandigarh today The Times of India Source: Author: | Date: 2025-08-22 18:39:00 Source: Author: | Date: 2025-08-22 18:39:00

AVT06, now approved for marketing in the EU as Mynzepli, is also under regulatory review in the United States and Japan. Image credit: ©artjazz – stock.adobe.com Advanz Pharma and Alvotech announced that the European Commission (EC) has approved marketing authorization for…

(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…

(Image Credit: AdobeStock/Ascannio The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025. The 2 regulatory submissions include a Chemistry, Manufacturing,…